Lutetium Lu 177 Dotatate Dosage

Medically reviewed by Drugs.com. Last updated on May 15, 2023.

Usual Adult Dose for Neuroendocrine Carcinoma

Intravenous infusion: 7.4 GBq (200 mCi) every 8 weeks for a total of 4 doses.

Premedication and Concomitant Medications:
Somatostatin Analogs:

• Discontinue long-acting somatostatin analogs (e.g., long-acting octreotide) for at least 4 weeks prior to initiating this drug. Administer short-acting octreotide as needed; discontinue at least 24 hours prior to initiating this drug.
• During treatment: Administer long-acting octreotide 30 mg intramuscularly 4 to 24 hours after each dose of this drug. Do not administer long-acting octreotide within 4 weeks of each subsequent dose. Short-acting octreotide may be given for symptomatic management during treatment with this drug, but must be withheld for at least 24 hours before each dose of this drug.
• Following treatment: Continue long-acting octreotide 30 mg intramuscularly every 4 weeks after completing this drug until disease progression or for up to 18 months following treatment initiation.

Antiemetic

• Administer antiemetics 30 minutes before the recommended amino acid solution.

Amino Acid Solution:

• Initiate an intravenous amino acid solution containing L-lysine and L-arginine 30 minutes before administering this drug.
• Use a three-way valve to administer amino acids using the same venous access as this drug or administer amino acids through a separate venous access in the patient's other arm.
• Continue the infusion during, and for at least 3 hours after infusion of this drug.
• Do not decrease the dose of the amino acid solution if the dose of this drug is reduced.

Comments:

• Dose modifications due to adverse reactions are provided in the dose adjustment section.
• Radiation Dosimetry: The maximum penetration in tissue is 2.2 mm and the mean penetration is 0.67 mm.

Use: Treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

Renal Dose Adjustments

Mild to moderate renal dysfunction:

• No adjustment recommended.
• Patients may be at greater risk of toxicity; frequent assessments of renal function should be performed.

Severe renal dysfunction (CrCl less than 30 mL/min) and ESRD: Safety has not been study.

If creatinine clearance is less than 40 mL/min, 40% increase, or 40% decrease in baseline serum creatinine:

• Withhold dose until complete or partial resolution.
• Resume this drug at 3.7 GBq (100 mCi) in patients with complete resolution.
• If reduced dose does not result in renal toxicity, administer this drug at 7.4 GBq (200 mCi) for next dose.
• Permanently discontinue this drug for renal toxicity requiring a treatment delay of 16 weeks or longer.
• Recurrent renal toxicity: Permanently discontinue this drug.

Liver Dose Adjustments

Mild to moderate liver dysfunction: No adjustment recommended.
Severe liver dysfunction (total bilirubin 3 times more the upper limit of normal and any AST): Safety has not been study.

If bilirubinemia is greater than 3 times the upper limit of normal (Grades 3 or 4) or hypoalbuminemia is less than 30 g/L with a decreased prothrombin ratio less than 70%:

• Withhold dose until complete or partial resolution.
• Resume this drug at 3.7 GBq (100 mCi) in patients with complete resolution.
• If reduced dose does not result in hepatotoxicity, administer this drug at 7.4 GBq (200 mCi) for next dose.
• Permanently discontinue this drug for hepatotoxicity requiring a treatment delay of 16 weeks or longer.
• Recurrent hepatotoxicity: Permanently discontinue this drug.

Dose Adjustments

Thrombocytopenia Grade 2, 3 or 4:

• Withhold dose until complete or partial resolution (Grade 0 to 1)
• Resume this drug at 3.7 GBq (100 mCi) in patients with complete or partial resolution.
• If reduced dose does not result in Grade 2, 3 or 4 thrombocytopenia toxicity, administer this drug at 7.4 GBq (200 mCi) for next dose.
• Permanently discontinue this drug for Grade 2 or higher toxicity requiring a treatment delay of 16 weeks or longer.
• Recurrent toxicity Grade 2, 3 or 4: Permanently discontinue this drug.

Anemia and Neutropenia Grade 3 or 4; Other Non-Hematologic Toxicity Grade 3 or 4:

• Withhold dose until complete or partial resolution: Anemia and Neutropenia (0, 1, or 2); Other Non-Hematologic Toxicity (0 to 2)
• Resume this drug at 3.7 GBq (100 mCi) in patients with complete or partial resolution.
• If reduced dose does not result in Grade 3 or 4 toxicity, administer this drug at 7.4 GBq (200 mCi) for next dose.
• Permanently discontinue this drug for Grade 3 or higher toxicity requiring a treatment delay of 16 weeks or longer.
• Recurrent Grade 3 or 4: Permanently discontinue this drug.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Handle with appropriate safety measures to minimize radiation exposure.
• Use aseptic technique, waterproof gloves, tongs, and radiation shielding when administering this drug.
• This drug should be used by or under the control of physicians qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.
• Do not administer as an intravenous bolus.
• During the infusion, ensure that the level of solution in the vial remains constant.
• The manufacturer product information should be consulted.

Reconstitution/preparation techniques:

• Do not inject directly into any other intravenous solution.
• Confirm the amount of radioactivity of this drug in the radiopharmaceutical vial with an appropriate dose calibrator prior to and after administration.
• Inspect the product visually for particulate matter and discoloration prior to administration under a shielded screen. Discard vial if particulates or discoloration are present.
• Dispose of any unused medicinal product or waste material in accordance with local and federal laws.
• The manufacturer product information should be consulted.

Patient advice:

• Patients should contact their healthcare provider for any signs or symptoms of myelosuppression or infection, such as fever, chills, dizziness, shortness of breath, or increased bleeding or bruising.
• There is a potential for secondary cancers, including myelodysplastic syndrome and acute leukemia.
• Patients should hydrate and urinate frequently during and after administration of this drug.
• Periodic laboratory tests to monitor for hepatotoxicity is recommended.
• Patients should contact their health care provider for signs or symptoms that may occur following tumor-hormone release, including severe flushing, diarrhea, bronchospasm, and hypotension.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer